In Nigeria, DMPA-SC—an easy-to-use injectable contraceptive commercially branded as Sayana Press—has been approved for provider- and self-injection, and is being distributed in the public and private sectors. With technical support from the USAID-funded HP+ and the Gates-funded Technical Support Unit, Nigeria’s Federal Ministry of Health applied a new impact model to quantify the potential family planning programmatic impact and cost implications of DMPA-SC introduction and scale-up in Nigeria by 2021. This brief highlights the boost that DMPA-SC can provide to the country’s modern contraceptive prevalence rate, cost savings, and next steps.
Health Policy Plus. 2018. DMPA-SC Introduction and Scale-Up in Nigeria: Future Benefits for Contraceptive Use and Savings. Washington, DC: Palladium, Health Policy Plus.
English PDF 977.5 kbMarch 2018